Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Study acronym: TIGeR-PaC
StatusActive, Not Recruiting
PhasePhase 3
SponsorRenovoRx
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jun 2026 → Jun 2027
See other at-risk trials from RenovoRx

Record History

The 50 most recent of 60 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Trial sites reduced: 42 → 31 locations
    • Eligibility criteria expanded, about 47 words
    • Secondary endpoints: details revised at 4 of 8 entries
  2. Primary completion pushed from Jun 2026 to Jun 2027
    • Study completion pushed from Sep 2026 to Sep 2027
    • Site details revised at 1 of 42 sites
    v59
  3. Site details revised at 1 of 42 sitesv58
  4. Eligibility criteria revised
    • Secondary endpoints revised (8)
    • Site details revised at 1 of 42 sites
    v57
  5. Study sites: 41 to 42v56
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 39 to 41v55
  2. Enrollment target: 320 to 190v54 Show 4 more changesShow less
    • Primary completion date: Sep 2022 to Jun 2026
    • Study sites: 37 to 39
    • Study completion date: Sep 2023 to Sep 2026
    • Eligibility criteria expanded, about 282 words
  3. Study sites: 36 to 37v53
  4. Eligibility criteria expanded, about 51 words
    • Site details revised at 13 of 36 sites
    v52
  5. Re-verified, no change to tracked fieldsv51
  6. Site details revised at 4 of 36 sitesv50
  7. Site details revised at 6 of 36 sitesv49
  8. Site contacts updated at 1 of 36 sitesv48
  9. Site contacts updated at 4 of 36 sitesv47
  10. Study sites: 35 to 36v46
  11. Site contacts updated at 1 of 35 sitesv45
  12. Study sites: 34 to 35v44
  13. Site details revised at 1 of 34 sitesv43
  14. Study sites: 33 to 34v42
  15. Site contacts updated at 1 of 33 sitesv41
  16. Site contacts updated at 1 of 33 sitesv40
  17. Site details revised at 8 of 33 sitesv39
  18. Study sites: 32 to 33v38
  19. Study sites: 31 to 32v37
  20. Eligibility criteria expanded, about 67 wordsv36
  21. Study sites revised (31)v35
  22. Study sites: 29 to 31v34
  23. Eligibility criteria expanded, about 113 wordsv33
  24. Site details revised at 5 of 29 sitesv32
  25. Study sites: 28 to 29v31
  26. Site contacts updated at 2 of 28 sitesv30
  27. Study sites: 27 to 28v29
  28. Study sites: 26 to 27v28
  29. Study sites: 25 to 26v27
  30. Study sites: 20 to 25v26
  31. Study sites: 19 to 20v25
  32. Enrollment target: 300 to 320v24
  33. Study sites: 18 to 19v23
  34. Study sites: 17 to 18v22
  35. Site details revised at 1 of 17 sitesv21
  36. Site contacts updated at 1 of 17 sitesv20
  37. Study sites: 16 to 17v19
  38. Site details revised at 4 of 16 sitesv18
  39. Site contacts updated at 1 of 16 sitesv17
  40. Study sites: 15 to 16v16
  41. Site details revised at 1 of 15 sitesv15
  42. Phase: Phase 4 to Phase 3
    • Site contacts updated at 4 of 15 sites
    v14
  43. Study sites: 14 to 15v13
  44. Study sites: 12 to 14v12
  45. Study sites: 11 to 12v11
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenovoRx
2 trials monitored
See 1 trial at risk
Pancreatic Cancer
1,740 trials monitored
See 105 trials at risk
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Trial Details
NCT Number NCT03257033
Lead Sponsor RenovoRx
Conditions
(from sponsor)		 Locally Advanced Pancreatic Cancer
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov